According to the listing prospectus, 200,000 shares - or 20% of the total 1 million registered shares recorded in the commercial - are the result of a capital increase.
Berna Biotech AG is a biotechnology company specialised in the development and production of immunobiological preparations, mainly viral and bacterial vaccines. The firm was founded in 1898 under the name of Schweiz. Serum- und Impfinstitut Bern. Among the company's key products in the marketplace are Nasaflu Berna and Inflexal Berna V vaccines, together with other vaccines that are under development such as Aerugen (Phase III clinical trials) and one for immunisation against hepatitis B (pre-clinical phase). Berna is involved in a number of alliances, among others with Aventis Pasteur.
In 2000, the company had 698 individuals under its employ and recorded operating income of CHF 151.7 million.
